The stock of GeneDx Holdings Corp (WGS) has seen a 1.82% increase in the past week, with a 44.44% gain in the past month, and a 75.93% flourish in the past quarter. The volatility ratio for the week is 8.28%, and the volatility levels for the past 30 days are at 7.41% for WGS. The simple moving average for the past 20 days is 14.14% for WGS’s stock, with a 153.51% simple moving average for the past 200 days.
Is It Worth Investing in GeneDx Holdings Corp (NASDAQ: WGS) Right Now?
WGS has 36-month beta value of 2.39. Analysts have mixed views on the stock, with 2 analysts rating it as a “buy,” 1 as “overweight,” 2 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for WGS is 19.13M, and currently, short sellers hold a 11.53% ratio of that float. The average trading volume of WGS on October 18, 2024 was 469.16K shares.
WGS) stock’s latest price update
The stock price of GeneDx Holdings Corp (NASDAQ: WGS) has plunged by -7.86 when compared to previous closing price of 60.78, but the company has seen a 1.82% gain in its stock price over the last five trading sessions. businesswire.com reported 2024-10-08 that STAMFORD, Conn.–(BUSINESS WIRE)–GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it has provided genomic newborn screenings (gNBS) for more than 14,000 infants through its participation in groundbreaking research studies which aim to explore the clinical utility and implementation of utilizing genome sequencing to expand standard newborn screening (NBS). Through these studies, GeneDx has conducted more gNBS than any other lab and.
Analysts’ Opinion of WGS
Many brokerage firms have already submitted their reports for WGS stocks, with Wells Fargo repeating the rating for WGS by listing it as a “Equal Weight.” The predicted price for WGS in the upcoming period, according to Wells Fargo is $34 based on the research report published on August 28, 2024 of the current year 2024.
Craig Hallum, on the other hand, stated in their research note that they expect to see WGS reach a price target of $43. The rating they have provided for WGS stocks is “Buy” according to the report published on July 10th, 2024.
Jefferies gave a rating of “Hold” to WGS, setting the target price at $21 in the report published on June 03rd of the current year.
WGS Trading at 38.90% from the 50-Day Moving Average
After a stumble in the market that brought WGS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -8.81% of loss for the given period.
Volatility was left at 7.41%, however, over the last 30 days, the volatility rate increased by 8.28%, as shares surge +37.76% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +92.44% upper at present.
During the last 5 trading sessions, WGS rose by +1.82%, which changed the moving average for the period of 200-days by +2,021.21% in comparison to the 20-day moving average, which settled at $49.06. In addition, GeneDx Holdings Corp saw 1936.36% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at WGS starting from OPKO HEALTH, INC., who proposed sale 13,404 shares at the price of $40.88 back on Sep 17 ’24. After this action, OPKO HEALTH, INC. now owns shares of GeneDx Holdings Corp, valued at $547,956 using the latest closing price.
Stueland Katherine, the Chief Executive Officer of GeneDx Holdings Corp, sale 10,501 shares at $37.59 during a trade that took place back on Sep 16 ’24, which means that Stueland Katherine is holding 103,706 shares at $394,733 based on the most recent closing price.
Stock Fundamentals for WGS
Current profitability levels for the company are sitting at:
- -0.37 for the present operating margin
- 0.5 for the gross margin
The net margin for GeneDx Holdings Corp stands at -0.48. The total capital return value is set at -0.28. Equity return is now at value -47.93, with -27.15 for asset returns.
Based on GeneDx Holdings Corp (WGS), the company’s capital structure generated 0.23 points at debt to capital in total, while cash flow to debt ratio is standing at -1.6. The debt to equity ratio resting at 0.3. The interest coverage ratio of the stock is -36.36.
Currently, EBITDA for the company is -127.83 million with net debt to EBITDA at -1.31. When we switch over and look at the enterprise to sales, we see a ratio of 6.45. The receivables turnover for the company is 9.3for trailing twelve months and the total asset turnover is 0.63. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.38.
Conclusion
To put it simply, GeneDx Holdings Corp (WGS) has had a better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
